SCHEMBL23933204

SCHEMBL23933204

CCOC(=O)c1cnc(Cc2cccc([N+](=O)[O-])c2)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.49
MAPT P10636 7/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 2/20 0.46
CDC7 O00311 1/20 0.46
DBF4 Q9UBU7 1/20 0.46
PDE4B Q07343 1/20 0.45
PDE4D Q08499 1/20 0.45
CACNA1F O60840 2/20 0.45
CACNA1D Q01668 2/20 0.45
CACNA1S Q13698 2/20 0.45
CACNA1C Q13936 2/20 0.45
ADORA3 P0DMS8 1/20 0.45
LMNA P02545 3/20 0.45
HIF1A Q16665 3/20 0.44
MAPK1 P28482 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29799652 0.82 CDC7 (0.49) MAPTKMT2AMEN1HTTCDC7
SCHEMBL28854648 0.82 CDC7 (0.49) MAPTKMT2AMEN1HTTCDC7
SCHEMBL14109414 0.80 PPP1CA (0.53) MAPTKMT2AMEN1RAB9ACDC7
SCHEMBL14109864 0.79 GPR52 (0.50) MAPTKMT2AMEN1CDC7DBF4
SCHEMBL26388109 0.78 CYP19A1 (0.47) RXFP1MAPTKMT2AMEN1RAB9A
SCHEMBL26388122 0.78 LMNA (0.50) MAPTKMT2AMEN1RAB9AHTT
SCHEMBL5528040 0.76 MAPT (0.50) RXFP1MAPTKMT2AMEN1RAB9A
SCHEMBL1920605 0.75 MAPT (0.52) MAPTKMT2AMEN1RAB9APDE4B
SCHEMBL2822552 0.75 CDC7 (0.68) MAPTRAB9ACDC7DBF4ALDH1A1
SCHEMBL30387029 0.73 TSHR (0.46) RXFP1KMT2AMEN1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4271387-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF Immunext, Inc. (US) 2023-11-08 EP disclosed
CN-117015381-A Novel steroid payloads, steroid linkers, ADCs containing the same and uses thereof 伊穆奈克斯特股份有限公司 2023-11-07 CN disclosed
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 US disclosed
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 US disclosed
CN-116096413-A Anti-human VISTA antibodies and uses thereof 伊穆奈克斯特股份有限公司 2023-05-09 CN disclosed
EP-4136118-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF Immunext, Inc. (US) 2023-02-22 EP disclosed
WO-2022150637-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF IMMUNEXT, INC. (US) 2022-07-14 WO disclosed
WO-2022150637-A1 NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF IMMUNEXT, INC. (US) 2022-07-14 WO disclosed
WO-2021216913-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT, INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A RXFP1 3259/4885MAPT 199/4885KMT2A 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.